Sustained-release vasodilator
Patent 4555398 Issued on November 26, 1985. Estimated Expiration Date: 
September 22, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 22, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3096248 3279996 3317394 3390050 3453360 3692896 3737521 InventorAssigneeApplicationNo. 06/534622 filed on 09/22/1983US Classes:514/307, Isoquinolines (including hydrogenated)424/425, Diffusion barrier is matrix514/211.07, Nitrogen attached directly or indirectly to the ring nitrogen of the seven-membered hetero ring by acyclic nonionic bonding (e.g., Diltiazem, etc.)514/255.04, Plural carbocyclic rings bonded directly to the same acyclic carbon atom which is attached directly or indirectly to the piperazine ring by nonionic bonding514/356, C=O in a C(=O)O group (e.g., nicotinic acid, etc.)514/532, Z-C(=O)-O-Y, wherein Z contains a benzene ring514/554Amine addition salt of the acidExaminersPrimary: Rose, Shep K.Attorney, Agent or FirmInternational ClassesA61K 9/00 (20060101)A61L 29/16 (20060101) A61L 29/00 (20060101) Foreign Application Priority Data1982-10-05 JPAbstractA vasodilator product having a sustained releasing function is produced by mixing and kneading an atoxic agent having vasodilating activity with a setting or thermoplastic resin and then molding them to form the molded product.Further, the vasodilator can be molded integratedly together with a medical device to be implanted into a human body. These vasodilators can be used not only for an operation of cerebral aneurysm, but also for drainage and vasodilator after microvascular anastomosis and endarterectomy. | |
